Journal: Nature Communications

Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

doi: 10.1038/s41467-026-69747-9

Figure Lengend Snippet: a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

Techniques: Derivative Assay, Control, Recombinant, Western Blot, Expressing, Transfection, In Vitro

Journal: Nature Communications

Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

doi: 10.1038/s41467-026-69747-9

Figure Lengend Snippet: a Experimental timeline for the establishment and treatment of the rat uterine scar model. b Schematic illustration and gross anatomical image of the rat uterine scar model. c H&E staining of uterine horns on days 14 and 30 post-surgery across sham, PBS, and rhctgf-treated groups ( n = 8 uterine horns per group). Red arrows indicate scar repair sites. Scale bars = 500 μm. d Immunohistochemical staining for α-smooth muscle actin (α-SMA) at incision sites on days 14 and 30. Red arrows mark the repaired myometrial regions. Scale bars = 500 μm. The regenerating myometrium originated from residual tissue flanking the incision and appeared thin, irregular, and fragmented. e Masson’s trichrome staining assessing collagen deposition at incision sites on days 14 and 30. Scale bars = 200 μm. Quantitative analysis of collagen fiber area was performed. f , g Efficiency of lrp1 knockdown in rat uterine fibroblasts assessed at the mRNA level. RT-qPCR and Western blot analyses show Collagen I and III expression in fibroblasts transfected with nc-siRNA or lrp1-siRNA and treated with rhctgf. Data are shown as mean ± SEM. The p values were calculated using a two-tailed unpaired Student’s t -test. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u .

Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

Techniques: Staining, Immunohistochemical staining, Knockdown, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Two Tailed Test

Journal: BMC Musculoskeletal Disorders

Article Title: ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model

doi: 10.1186/1471-2474-11-221

Figure Lengend Snippet: ARG098 cytotoxicity to human chondrocytes . (A) ARG098 binding activity to human chondrocytes was assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of human chondrocytes following ARG098 treatment (Experiment 1: from 0.1 to 1000 ng/mL, Experiment 2: from 1 to 100 μg/mL) versus untreated condition, as measured by the WST assay. Black circles and black triangles, ARG098; white circles and white triangles, human IgM. Each point represents mean ± SEM (n = 5).

Article Snippet: The sources of the other materials used in this study are as follows: human IgM was obtained from ICN Biomedicals Inc. (Aliso Viejo, CA, USA), chondrocyte basal medium supplemented with chondrocyte growth supplement was obtained from Cell Applications, Inc. (San Diego, CA, USA), and the neutralizing antibody anti-human APO-1/Fas (SM1/23) was obtained from Bender Medsystems GmbH (Vienna, Austria).

Techniques: Binding Assay, Activity Assay, Staining, WST Assay